Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials

NCT06489015 | Active Not Recruiting Early Phase 1

• 1 other identifier: rHSA2024-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 5

Brief Summary

This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin (rHSA, hereafter referred to as the "investigational drug") in patients with mild to moderate Alzheimer's Disease (AD). It aims to enroll 30 subjects who meet the 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for "Probable AD Dementia." Participants will be randomized in a 1:1:1 ratio to receive the investigational drug at doses of 20g, 30g, or 40g, for assessments of safety and preliminary efficacy. Stratification factors will be based on the severity classification (mild; moderate) as indicated by the total score on the Clinical Dementia Rating Scale - Global Score (CDR-GS) during the screening period.

Conditions

Alzheimer's Disease (AD)

Outcome Measures

Primary Outcomes (1)

• The change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) score from baseline to Week 25 post-treatment.

  from baseline to Week 25 post-treatment

Secondary Outcomes (4)

• The changes in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) scores from baseline at Weeks 7, 16, 29 (if applicable), 37 (if applicable), and 41 (if applicable) post-treatment.

  At Weeks 7, 16, 25, 29 (if applicable), 37 (if applicable), and 41 (if applicable)

• The changes in Clinical Dementia Rating Scale - Global Score (CDR-GS) from baseline at Weeks 7, 16, 25, 29 (if applicable), 37 (if applicable), and 41 (if applicable) following treatment initiation.

  At Weeks 7, 16, 25, 29 (if applicable), 37 (if applicable), and 41 (if applicable)

• The changes in Neuropsychiatric Inventory (NPI) scores from baseline at Weeks 7, 16, 25, 29 (if applicable), 37 (if applicable), and 41 (if applicable) after the commencement of treatment.

  At Weeks 7, 16, 25, 29 (if applicable), 37 (if applicable), and 41 (if applicable)

• The changes in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) ability assessment scale scores from baseline

  At Weeks 7, 16, 25, 29 (if applicable), 37 (if applicable), and 41 (if applicable)

Other Outcomes (4)

• blood albumin concentration

  At baseline (D0), 12 hours after the 5th dosing (W13D1), and 12 hours after the 9th dosing (W25D1)、12 hours following CSF collection

• oxidation level of serum albumin

  At baseline (D0), 12 hours after the 5th dosing (W13D1), and 12 hours after the 9th dosing (W25D1)、12 hours following CSF collection

• cerebrospinal fluid albumin concentration

  At baseline (D0) and 12 hours following any dosing event between W13D1 and W25D1 during the treatment period

Study Arms (3)

20g dose group

EXPERIMENTAL

Drug: Recombinant Human Serum Albumin

30g dose group

EXPERIMENTAL

Drug: Recombinant Human Serum Albumin

40g dose group

EXPERIMENTAL

Drug: Recombinant Human Serum Albumin

Interventions

Recombinant Human Serum Albumin DRUG

Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.

20g dose group; 30g dose group; 40g dose group

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged between 50 and 85 years (inclusive), with no gender restrictions;
• Meet the 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for "Probable AD Dementia";
• Mild to moderate disease stage, as indicated by a Clinical Dementia Rating Scale - Global Score (CDR-GS) ≤ 2;
• Hachinski Ischemia Scale (HIS) ≤ 4;
• Geriatric Depression Scale (GDS) score between 0 and 10 (inclusive);
• Memory impairment present for at least 12 months with evidence of progression;
• Availability of a qualified brain MRI scan within 1 month prior to enrollment, or willingness to undergo an MRI scan, showing: No more than 2 infarcts larger than 2 cm, no infarcts in key areas such as the thalamus, hippocampus, entorhinal cortex, perirhinal cortex, angular gyrus, cortical or subcortical gray matter nuclei, and imaging features highly suggestive of Alzheimer's Disease (Medial Temporal Lobe Atrophy \[MTA\] scale rating ≥ 2);
• Female participants must be postmenopausal for at least 24 weeks, have undergone sterilization surgery, or if of childbearing potential, along with fertile males, agree to use effective contraception during the study. Women of childbearing potential or those postmenopausal for less than 24 weeks require a negative pregnancy test at screening;
• If patients were on Alzheimer's medications such as cholinesterase inhibitors, NMDA receptor antagonists, or Oligomannate capsules, or taking other drugs that could affect cognition (e.g., Ginkgo biloba, Ginkgo leaf extract, Vitamin E, Selegiline, Folic acid, Estrogen, traditional Chinese medicines including compound sea snake capsules, Citicoline, Piracetam, Aniracetam, etc.), they must have been on a stable dose for at least 30 days before screening, with the investigator determining suitability and the patient agreeing to maintain this stable dose throughout the trial;
• Patients must have a stable and dependable caregiver or adequate care arrangements (a minimum of 4 days weekly, 2 hours daily), with the caregiver willing to assist in the patient's full participation in the trial, including accompanying them to visits and helping with assessment scales;
• Patients should have an educational level of primary school completion or above, capable of completing cognitive assessments and other tests as required by the protocol;
• Written informed consent obtained.

You may not qualify if:

• Dementia secondary to other causes: frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson's disease dementia, dementia due to epilepsy, post-traumatic dementia, central nervous system infections, and immune-mediated dementias, among others;
• Known history of allergy or allergic reactions to yeast or yeast-derived products, any component of the study formulation, individuals with an allergic constitution (multiple drug or food allergies), a history of severe systemic allergic reactions to biologics, or those deemed unsuitable for trial drug treatment by the investigator;
• Active or historical cardiovascular disorders at screening or conditions deemed inappropriate for human albumin treatment by the investigator, specifically including but not limited to: hypertension (systolic blood pressure \>160 mmHg or diastolic \>100 mmHg, unless well-controlled with medication and stable in the investigator's judgment), severe anemia, acute cardiac events, significant heart or pulmonary structural diseases, severe arrhythmias, decompensated heart failure (in normal or high volume states), unstable angina, myocardial infarction within 6 months prior to screening, medically treated tachycardia/bradycardia, third-degree atrioventricular block, etc.;
• Active metabolic disorders or history thereof at screening, or concurrent renal impairment deemed unsuitable for serum albumin therapy by the investigator, such as diabetic kidney disease, hyperuricemia-related renal injury, sleep apnea-associated renal damage, hyperlipidemia-induced renal impairment, etc.;
• Presence of severe underlying diseases at screening that the investigator deems inappropriate for study participation, including but not limited to active malignancy, pulmonary edema, bleeding tendencies or active bleeding disorders, uncontrolled infections (including spontaneous bacterial peritonitis), thyroid dysfunction (Grade 3 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\], version 5.0), etc.;
• Positive for hepatitis B surface antigen (HBsAg), positive for hepatitis B core antibody (HBcAb) with detectable hepatitis B virus deoxyribonucleic acid (HBV-DNA), positive for hepatitis C antibody (HCV Ab) with detectable hepatitis C ribonucleic acid (HCV-RNA), positive for human immunodeficiency virus antibody (HIV Ab), or positive for Treponema pallidum (syphilis) antibodies at screening;
• Presence of the following laboratory abnormalities at screening:
• Liver function: Alanine transaminase (ALT) \>3 times the upper limit of normal (ULN); Aspartate transaminase (AST) \>3 ULN; Total bilirubin (TBIL) \>1.5 ULN or deemed unsuitable for the trial by the investigator;
• Renal function: Creatinine clearance (Ccr) \<50 mL/min (calculated using the Cockcroft-Gault formula: Ccr(mL/min) = \[(140 - age) × weight(kg)\] / \[72 × Scr(mg/dL)\], multiplied by 0.85 for females);
• Bone marrow function: Absolute neutrophil count (ANC) \<1.5 × 10\^9/L; Platelets (PLT) \<100 × 10\^9/L; Hemoglobin (HGB) \<90 g/L;
• History or presence of neurological disorders at screening, such as stroke, neuromyelitis optica, Parkinson's disease, epilepsy, etc.;
• Patients with comorbid psychiatric disorders, including schizophrenia or other mental illnesses, bipolar disorder, depression, or delirium;
• Contraindications to MRI scanning, including incompatible cardiac pacemakers/defibrillators, magnetic metal implants, etc.;
• Irreversible visual or auditory impairments preventing completion of assessments related to cognition, neuropsychiatric symptoms, and activities of daily living;
• Alcohol or drug abusers;

Sponsors & Collaborators

• Protgen Ltd: lead

Study Sites (5)

Luoyang Third People's Hospital

Luoyang, Henan, 471002, China

Location

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

Location

Wuhan Union Hospital of China

Wuhan, Hubei, 430000, China

Location

Clinical Medical College & Affiliated Hospital Of Jiujiang University

Jiujiang, Jiangxi, 332000, China

Location

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, 200000, China

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

recombinant human serum albumin-heme

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 26, 2024
• First Posted: July 5, 2024
• Study Start: June 28, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: March 11, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (5)